Skip to main content

Table 2 Relationship between artemisinin derivatives and mortality, neurologic deficits at discharge, and death or readmission in follow-up

From: Parenteral artemisinins are associated with reduced mortality and neurologic deficits and improved long-term behavioral outcomes in children with severe malaria

 

In-hospital mortality a

Neurologic deficit at discharge in children with cerebral malariab

Death or readmission 6 months of follow-up c

OR (95% CI)

aOR (95% CI)

P

OR (95% CI)

aOR (95% CI)

P

OR (95% CI)

aOR (95% CI)

P

Antimalarial class

 Quinine

Reference

Reference

 

Reference

References

 

Reference

Reference

 

 Artemisinin

0.51 (0.22, 1.20)

0.22 (0.07, 0.67)

0.008

0.44 (0.24, 0.81)

0.28 (0.13, 0.59)

0.0007

2.09 (1.22, 3.58)

1.24 (0.68, 2.27)

0.49

Antimalarial medication

 Quinine

Reference

Reference

 

Reference

Reference

 

Reference

Reference

 

 Quinine + Artemether

0.62 (0.21, 1.83)

0.28 (0.08, 0.97)

0.05

0.29 (0.13, 0.67)

0.18 (0.07, 0.48)

0.0005

1.88 (0.93, 3.78)

1.47 (0.68, 3.17)

0.33

 Artemether

0.36 (0.05, 2.77)

0.12 (0.01, 1.49)

0.10

0.79 (0.22, 2.82)

0.50 (0.12, 2.13)

0.35

5.49 (2.44, 12.4)

3.88 (1.56, 9.69)

0.004

 Artesunate

0.45 (0.10, 1.93)

0.17 (0.02, 1.55)

0.12

0.69 (0.25, 1.94)

0.51 (0.14, 1.83)

0.30

0.96 (0.36, 2.58)

0.30 (0.10, 0.90)

0.03

  1. aAdjusted for age, sex, disease group (cerebral malaria or severe malarial anemia), respiratory distress, acute kidney injury, hemoglobin, log base 10 transformed lactate dehydrogenase and total bilirubin concentrations on admission, and enrollment in the iron study (not enrolled, enrolled in the immediate iron arm, enrolled in the delayed iron arm)
  2. bAdjusted for age, sex, duration of coma, number of seizures during hospitalization, acute kidney injury, and enrollment in the iron study (not enrolled, enrolled in the immediate iron arm, enrolled in the delayed iron arm)
  3. cAdjusted for age, sex, disease group (cerebral malaria or severe malarial anemia), hemoglobin on admission, receiving a transfusion in-hospital, and enrollment in the iron study (not enrolled, enrolled in the immediate iron arm, enrolled in the delayed iron arm)